MAFbx and MuRF1 mRNA expression and its relationship with muscular contractility following free muscle transfer.
- Author:
An-Tang LIU
1
;
Da-Zhi YU
;
Ying-Fan ZHANG
;
Wen-Jun ZHANG
;
Wei-Jin DING
;
An-Jing REN
;
Chao-Ping FANG
;
Hua JIANG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Female; Muscle Contraction; Muscle Proteins; genetics; Muscle, Skeletal; pathology; Muscular Atrophy; genetics; metabolism; pathology; RING Finger Domains; RNA, Messenger; genetics; Rats; Rats, Sprague-Dawley; SKP Cullin F-Box Protein Ligases; genetics; Tripartite Motif Proteins; Ubiquitin-Protein Ligases; genetics
- From: Chinese Journal of Plastic Surgery 2009;25(3):217-221
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study muscle atrophy F-box (MAFbx) and muscle ring finger 1 (MuRF1) mRNA expression and its relationship with muscular contraction following free muscle transfer.
METHODSThe gracilis muscle was orthotopic transferred in adult rat to establish the animal model. The muscle at the unoperated side was used as control. The expression of MAFbx and MuRF1 mRNA, the muscle contraction and muscle function were measured by real-time PCR and multiple function physiological device. The relationship among the expression of MAFbx and MuRF1 mRNA, the muscle contraction and muscle function was analyzed.
RESULTSAfter muscle free transfer, muscle wet weight reservation, the maximum contraction and tetanus strength reduce first and increased later, but still lower than those at control side. The expression of MAFbx and MuRF1 mRNA reached peak level 3 - 4 weeks after muscle transfer which was 7.1 and 4.1 times as that at control side. It decreased later, but still higher than that at control side, showing a significant difference between them (P< 0. 05).
CONCLUSIONSPersistent over-expression of MAFbx and MuRF1 mRNA after muscle transfer has a close relationship with muscle atrophy and muscle dysfunction. MAFbx and MuRF1 can be used as markers for early muscle atrophy, and also as potential target for drug treatment of muscle atrophy.